sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_0060224> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_0060224> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00908> ;
    a rdf:Statement ;
    rdfs:label "conversion of atrial fibrillation flutter in patients with symptomatic atrial fibrillation flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response quinidine gluconate is indicated as a means of restoring normal sinus rhythm if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time see dosage and administration reduction of frequency of relapse into atrial fibrillation flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation flutter generally patients who have had previous episodes of atrial fibrillation flutter that were so frequent and poorly tolerated as to outweigh in the judgment of the physician and the patient the risks of prophylactic therapy with quinidine gluconate the increased risk of death should specifically be considered quinidine gluconate should be used only after alternative measures e g use of other drugs to control the ventricular rate have been found to be inadequate in patients with histories of frequent symptomatic episodes of atrial fibrillation flutter the goal of therapy should be an increase in the average time between episodes in most patients the tachyarrhythmia will recur suppression of ventricular arrhythmias quinidine gluconate is also indicated for the suppression of recurrent documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are life threatening because of the proarrhythmic effects of quinidine its use with ventricular arrhythmias of lesser severity is generally not recommended and treatment of patients with asymptomatic ventricular premature contractions should be avoided where possible therapy should be guided by the results of programmed electrical stimulation and or holter monitoring with exercise antiarrhythmic drugs including quinidine gluconate have not been shown to enhance survival in patients with ventricular arrhythmias" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation nkg:SymptomaticReliefIndication .
  <https://identifiers.org/drugbank:DB00908> bl:category bl:Drug .
}